ABVX - Wutah dodolan YoY (TTM) ABIVAX

Logistics disruptions and sanctions are severely hindering component deliveries and global tests for ABIVAX (ABVX). The year-over-year sales growth percentage (over 4 quarters) illustrates the market response, where 0.00 reflects the most recent metric value. The business potential relies on the launch of obefeximod for the treatment of colitis, with development funded by capital without the use of M&A strategies.
abivax.com (ABVX) - rincian metrik lan laporan keuangan

For ABIVAX, which is developing an ecosystem of experimental drugs, the chart of year-over-year sales volume changes for the LTM serves as an indicator of the commercial realization of its molecules. This metric measures revenue dynamics over a rolling twelve-month period, providing continuous monitoring without quarterly gaps. The calculation is based on a sub-daily comparison of the current revenue stream against the same period last year. Currently, the business's financial value depends entirely on the verdicts of the FDA and EMA.